Taiwan · Delayed Price · Currency is TWD Allied Biotech Statistics
Total Valuation
Allied Biotech has a market cap or net worth of TWD 2.38 billion. The enterprise value is 2.25 billion.
| Market Cap | 2.38B |
| Enterprise Value | 2.25B |
Important Dates
The next estimated earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Jun 4, 2026 |
Share Statistics
Allied Biotech has 96.24 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 96.24M |
| Shares Outstanding | 96.24M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | -0.26% |
| Owned by Insiders (%) | 9.11% |
| Owned by Institutions (%) | 12.89% |
| Float | 56.47M |
Valuation Ratios
The trailing PE ratio is 22.24.
| PE Ratio | 22.24 |
| Forward PE | n/a |
| PS Ratio | 2.70 |
| PB Ratio | 1.87 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | 16.49 |
| P/OCF Ratio | 12.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.73, with an EV/FCF ratio of 15.62.
| EV / Earnings | 21.01 |
| EV / Sales | 2.56 |
| EV / EBITDA | 11.73 |
| EV / EBIT | 17.21 |
| EV / FCF | 15.62 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.79 |
| Quick Ratio | 1.18 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 5.04 |
| Interest Coverage | 8.03 |
Financial Efficiency
Return on equity (ROE) is 8.46% and return on invested capital (ROIC) is 9.07%.
| Return on Equity (ROE) | 8.46% |
| Return on Assets (ROA) | 3.63% |
| Return on Invested Capital (ROIC) | 9.07% |
| Return on Capital Employed (ROCE) | 9.93% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | 22.00M |
| Profits Per Employee | 2.68M |
| Employee Count | 40 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.10 |
Taxes
In the past 12 months, Allied Biotech has paid 29.66 million in taxes.
| Income Tax | 29.66M |
| Effective Tax Rate | 21.68% |
Stock Price Statistics
The stock price has increased by +29.13% in the last 52 weeks. The beta is 0.17, so Allied Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +29.13% |
| 50-Day Moving Average | 29.81 |
| 200-Day Moving Average | 24.71 |
| Relative Strength Index (RSI) | 30.76 |
| Average Volume (20 Days) | 397,472 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Allied Biotech had revenue of TWD 880.06 million and earned 107.16 million in profits. Earnings per share was 1.11.
| Revenue | 880.06M |
| Gross Profit | 317.17M |
| Operating Income | 130.82M |
| Pretax Income | 136.81M |
| Net Income | 107.16M |
| EBITDA | 186.27M |
| EBIT | 130.82M |
| Earnings Per Share (EPS) | 1.11 |
Balance Sheet
The company has 852.38 million in cash and 725.99 million in debt, with a net cash position of 126.40 million or 1.31 per share.
| Cash & Cash Equivalents | 852.38M |
| Total Debt | 725.99M |
| Net Cash | 126.40M |
| Net Cash Per Share | 1.31 |
| Equity (Book Value) | 1.27B |
| Book Value Per Share | 13.24 |
| Working Capital | 680.84M |
Cash Flow
In the last 12 months, operating cash flow was 184.15 million and capital expenditures -40.02 million, giving a free cash flow of 144.13 million.
| Operating Cash Flow | 184.15M |
| Capital Expenditures | -40.02M |
| Depreciation & Amortization | 55.45M |
| Net Borrowing | -224.01M |
| Free Cash Flow | 144.13M |
| FCF Per Share | 1.50 |
Margins
Gross margin is 36.04%, with operating and profit margins of 14.86% and 12.18%.
| Gross Margin | 36.04% |
| Operating Margin | 14.86% |
| Pretax Margin | 15.55% |
| Profit Margin | 12.18% |
| EBITDA Margin | 21.17% |
| EBIT Margin | 14.86% |
| FCF Margin | 16.38% |
Dividends & Yields
This stock pays an annual dividend of 1.25, which amounts to a dividend yield of 5.06%.
| Dividend Per Share | 1.25 |
| Dividend Yield | 5.06% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 89.61% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 4.96% |
| Earnings Yield | 4.51% |
| FCF Yield | 6.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Allied Biotech has an Altman Z-Score of 2.46 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.46 |
| Piotroski F-Score | 7 |